Stockscreener 앱 받기
2.75
12.20%
0.29
전일 마감가:
$2.46
열려 있는:
$2.51
하루 거래량:
781.21K
Relative Volume:
0.70
시가총액:
$177.04M
수익:
-
순이익/손실:
$-36.95M
주가수익비율:
-3.2738
EPS:
-0.84
순현금흐름:
$-33.46M
1주 성능:
+22.67%
1개월 성능:
+31.43%
6개월 성능:
-57.28%
1년 성능:
-70.95%
1일 변동 폭
$2.47
$2.77
1주일 범위
$2.12
$2.77
52주 변동 폭
$1.61
$11.20
Larimar Therapeutics Inc Stock (LRMR) Company Profile
명칭
Larimar Therapeutics Inc
전화
844-511-9056
주소
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
LRMR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
2.765 | 147.26M | 0 | -36.95M | -33.46M | -0.84 |
|
ONC
Beone Medicines Ltd Adr
|
256.86 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.03 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2213 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.28 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
497.53 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-29 | 개시 | Truist | Buy |
| 2024-10-16 | 개시 | Oppenheimer | Outperform |
| 2024-10-03 | 개시 | Wedbush | Outperform |
| 2024-10-02 | 개시 | H.C. Wainwright | Buy |
| 2024-09-04 | 개시 | Robert W. Baird | Outperform |
| 2024-04-03 | 개시 | Leerink Partners | Outperform |
| 2023-11-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-10-19 | 개시 | Guggenheim | Buy |
| 2022-02-15 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-02-10 | 개시 | JMP Securities | Mkt Outperform |
| 2021-02-01 | 개시 | William Blair | Outperform |
모두보기
Larimar Therapeutics Inc 주식(LRMR)의 최신 뉴스
ProShare Advisors LLC Purchases Shares of 14,870 Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
Larimar Therapeutics, Inc.’s (LRMR): Analysts See 957% Upside Potential - MSN
Larimar Therapeutics’ SWOT analysis: nomlabofusp’s potential lifts FA stock By Investing.com - Investing.com South Africa
Larimar Therapeutics’ SWOT analysis: nomlabofusp’s potential lifts FA stock - Investing.com
Traws Pharma Highlights Q1 2025 Financial Progress and Antiviral Developments - MyChesCo
Larimar Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development - MSN
Larimar Therapeutics Advances Nomlabofusp Amid Financial Loss - TipRanks
Larimar Therapeutics Inc (NASDAQ: LRMR): Can A Stock Be -26.10% Lower Year-To-Date And Still Be A Loser? - Marketing Sentinel
The time has not yet come to remove your chips from the table: Larimar Therapeutics Inc (LRMR) - Sete News
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Humana (HUM) and Larimar Therapeutics (LRMR) - The Globe and Mail
Stock Traders Buy High Volume of Call Options on Larimar Therapeutics (NASDAQ:LRMR) - Defense World
LRMR: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
Larimar Therapeutics Inc (LRMR)’s highs and lows: A closer look at its stock price fluctuations - uspostnews.com
Larimar: Q1 Earnings Snapshot - MySA
Larimar Therapeutics, Inc. SEC 10-Q Report - TradingView
Investor’s Delight: Larimar Therapeutics Inc (LRMR) Closes Strong at 2.39, Up 1.70 - DWinneX
Larimar (LRMR) Advances Clinical Program Towards Potential FDA A - GuruFocus
Investing in Larimar Therapeutics Inc (LRMR) Is Getting More Attractive - knoxdaily.com
Larimar (LRMR) Advances Clinical Program Towards Potential FDA Approval | LRMR Stock News - GuruFocus
Larimar Therapeutics Reports First Quarter 2025 Financial Results - GlobeNewswire
Larimar's Friedreich's Ataxia Drug Gets FDA Accelerated Approval Path While Cash Reserves Surge - Stock Titan
Larimar Therapeutics awards key executives performance-based stock - MSN
Market Watch Highlights: Larimar Therapeutics Inc (LRMR) Ends on an Upturn Note at 2.38 - DWinneX
Larimar Therapeutics Inc (LRMR) Stock: A Comprehensive 52-Week Review - investchronicle.com
Nothing is Better Than Larimar Therapeutics Inc (LRMR) stock at the moment - Sete News
The Potential Rise in the Price of Larimar Therapeutics Inc (LRMR) following insiders activity - knoxdaily.com
Larimar Therapeutics Inc (LRMR)’s results reveal risk - uspostnews.com
Larimar Therapeutics: Initiating Hold Rating With Upcoming Catalysts - Seeking Alpha
An In-Depth Look at Larimar Therapeutics Inc Inc. (LRMR) Price Performance During Market Crashes - investchronicle.com
Larimar to seek accelerated approval of FA therapy nomlabofusp this year - Friedreich's Ataxia News
Q1 EPS Estimate for Larimar Therapeutics Lowered by Analyst - MarketBeat
Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth? - Yahoo Finance
Larimar Therapeutics Advances Nomlabofusp Program Amid Regulatory Support - MSN
Larimar Therapeutics (NASDAQ:LRMR) Given Buy Rating at Guggenheim - Defense World
HC Wainwright Issues Positive Forecast for Larimar Therapeutics (NASDAQ:LRMR) Stock Price - Defense World
Larimar Therapeutics Inc (NASDAQ: LRMR) Shares Might Go Down -73.01% This Year - Marketing Sentinel
Larimar Therapeutics (NASDAQ:LRMR) Price Target Cut to $10.00 by Analysts at Robert W. Baird - Defense World
Jones Trading maintains $14 target on Larimar Therapeutics stock By Investing.com - Investing.com UK
Larimar Therapeutics Reports 2024 Financial Results and Development Progress - TipRanks
FDA open to new surrogate endpoint for FA drug approval By Investing.com - Investing.com Australia
Larimar: Q4 Earnings Snapshot - mySA
Wedbush Cuts Price Target on Larimar Therapeutics to $17 From $22, Maintains Outperform Rating - MarketScreener
FDA open to new surrogate endpoint for FA drug approval - Investing.com India
Larimar: Q4 Earnings Snapshot -March 24, 2025 at 07:17 am EDT - MarketScreener
Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Breakthrough: FDA Opens Door for Faster Approval of Larimar's Rare Disease Treatment - Stock Titan
Larimar Therapeutics Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Larimar Therapeutics Inc (LRMR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.30%
3.35%
자본화:
|
볼륨(24시간):